Results 1 to 10 of about 590 (119)
JID Innovations, 2023 Tralokinumab, a fully human mAb specifically targeting the IL-13 cytokine, has demonstrated clinical efficacy and safety in patients with moderate-to-severe atopic dermatitis. Tralokinumab binds IL-13 with high affinity, which prevents the interaction of
Maxim A.X. Tollenaere +6 more
doaj +2 more sources
Frontiers in PharmacologyBackgroundTralokinumab, a humanized monoclonal antibody targeting interleukin-13, has been primarily used for the treatment of moderate-to-severe atopic dermatitis.
Kaidi Zhao, Shengxiang Xiao, Chen Tu
exaly +3 more sources
Clinical, Cosmetic and Investigational DermatologyGiuseppe Lauletta,1 Luca Potestio,1 Cataldo Patruno,2 Mario De Lucia,1 Maddalena Napolitano1 1Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 2Department of Medicine and Health ...
Maddalena Napolitano, Luca Potestio
exaly +2 more sources
Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab
Dermatology and Therapy, 2023 Introduction IL-13 is the primary upregulated cytokine in atopic dermatitis (AD) skin and is the pathogenic mediator driving AD pathophysiology. Lebrikizumab, tralokinumab and cendakimab are therapeutic monoclonal antibodies (mAb) that target IL-13 ...
Angela J. Okragly +6 more
doaj +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2022 Therapeutic IgG4 antibodies engage in Fab‐arm exchange with endogenous human immunoglobulin G4 (IgG4) to form monovalent hybrid molecules. A mechanistic population model was developed to quantitatively characterize the dynamic Fab‐arm exchange of ...
Bing Wang, Jo Goodman, Lorin K. Roskos
doaj +1 more source
Selective IL-13 inhibitors for the treatment of atopic dermatitis
Drugs in Context, 2021 Background: Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. AD pathogenesis is multifactorial, involving environmental and genetic factors.
Francisca Gonçalves +2 more
doaj +1 more source
Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma. [PDF]
PLoS ONE, 2017 Interleukin-13 (IL-13) is associated with allergic airway inflammation and airway remodeling. Our group found a variant with a single nucleotide polymorphism in the IL13 gene at position +2044G>A (rs20541) that was expected to result in the non ...
Yutaka Nakamura +3 more
doaj +1 more source
Clinical trials of antibody drugs in the treatments of atopic dermatitis
Frontiers in Medicine, 2023 Atopic dermatitis (AD) is one of the most common, relapsing, chronic inflammatory skin disease, being regarded as a global health issue. Recent studies have shown that Th2 cell-mediated type 2 immunity plays a central role in AD.
Guihao Zhou, Yueyao Huang, Ming Chu
doaj +1 more source
Frontiers in ImmunologyObjectivesDupilumab and tralokinumab are FDA-approved biological agents for the treatment of atopic dermatitis (AD). This study analyzed tralokinumab-related adverse events (AEs) reported by healthcare professionals, utilizing data mined from the FDA ...
Yueping Jiang, Xinjuan Sun, Yang Li
doaj +1 more source
Frontiers in Immunology, 2022 BackgroundSeveral clinical trials have evaluated the efficacy and safety of interleukin-13 (IL-13) with lebrikizumab and tralokinumab in patients with moderate to severe atopic dermatitis (AD).
Yan Zhang +11 more
doaj +1 more source